StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Aggregate of 16 sell-side ratings as of 2026-05-01. Stonvex does not endorse these ratings.
Earnings (▲ beat / ▼ miss) and ex-dividend dates plotted on the price line. Educational — proximity does not establish causation.
Next report date, year-over-year trend, and recent quarter history.
Finnhub hasn't published the next scheduled earnings date yet. The list typically populates 4–8 weeks before the call.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-14 | $5.55 | $5.63 | +1.44% | 0.4M |
| 05-15 | $5.53 | $5.68 | +2.71% | 0.6M |
| 05-18 | $5.71 | $6.00 | +5.08% | 0.7M |
| 05-19 | $5.93 | $5.95 | +0.34% | 0.5M |
| 05-20 | $5.93 | $6.16 | +3.88% | 0.5M |
RxSight Inc is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture, and sale of light adjustable lenses and related capital equipment.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Each factor shows RXST's percentile within the scored universe — observational ranking, not a recommendation.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Past 1 reported quarters: EPS surprise vs estimate and the day-after-release stock reaction. Past performance does not predict future moves.
Sources: Finnhub earnings calendar + Polygon daily aggregates. Reaction direction can diverge from EPS surprise (guidance, macro, or sector flow can dominate the next-day print).
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $30.89M | $134.48M | $101.87M | $71.53M |
Operating Income | $-17.83M | $-48.19M | $-36.85M | $-24.68M |
Net Income | $-15.88M | $-38.94M | $-29.79M | $-11.79M |
EPS (Diluted) | $-0.38 | $-0.95 | $-0.73 | $-0.49 |
Total Assets | $303.99M | $311.81M | $308.53M | $309.01M |
Total Liabilities | $36.70M | $36.13M | $32.56M | $31.00M |
Cash & Equivalents | $17.57M | $19.95M | $29.63M | $40.35M |
Free Cash Flow OCF − CapEx | $-11.65M | $-19.34M | $-17.09M | $-15.32M |
Shares Outstanding | 41.38M | 41.24M | 41.08M | 40.91M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.